P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3

oleh: A. M. Lesokhin, B. Arnulf, R. Niesvizky, M. Mohty, N. J. Bahlis, M. H. Tomasson, P. Rodrίguez-Otero, H. Quach, N. S. Raje, S. Iida, M.-S. Raab, A. Czibere, S. Sullivan, E. Leip, A. Viqueira, X. Leleu